Veloxis Pharmaceuticals A/S Announces Financial Results for the First Half 2013
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
To: NASDAQ OMX Copenhagen A/S -- LCP-Tacro™ has successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety endpoints. The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
Help employers find you! Check out all the jobs and post your resume.
To: NASDAQ OMX Copenhagen A/S -- LCP-Tacro™ has successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety endpoints. The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
Help employers find you! Check out all the jobs and post your resume.